NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
UNC Lineberger Comprehensive Cancer Center
BeiGene
Cantonal Hospital of St. Gallen
pharmaand GmbH
Amgen
Amgen
Merck KGaA, Darmstadt, Germany